Compare iShares Core High Dividend ETF (HDV) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Smith & Nephew plc — how do they compare? iShares Core High Dividend ETF trades at $28.78 (market cap $14.68B), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: iShares Core High Dividend ETF is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares Core High Dividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and Smith & Nephew plc for 120 Days on average.
| HDV | SNN | |
|---|---|---|
Market Cap | $14.68B | $11.10B |
Volume | 2,925,562 | 1,051,703 |
52-Week High | $29.93 | $37.17 |
52-Week Low | $23.64 | $26.42 |
Typical Hold Time | 117 Days | 120 Days |
Sector | — | Health |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.28, down 0.28% on the day, with technical indicators showing a neutral to bearish bias. The ETF recently underwent a significant sector rebalancing, reducing healthcare exposure by nearly half while increasing energy, staples, and utilities. This shift creates heightened concentration risk with 62% of assets in just three sectors, offering a 3% yield that may not adequately compensate for reduced diversification according to Seeking Alpha analysis from September 28, 2026.
The outlook remains cautious as HDV's sector concentration and modest yield face headwinds from rising interest rates. While high-dividend ETFs are outperforming the S&P 500 in 2026 according to 24/7 Wall Street, HDV's structural changes introduce execution risk. Investors should weigh the trade-off between current income and long-term diversification benefits, particularly as the Fed continues tightening monetary policy.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
